LPCN 1154A for Postpartum Depression Treatment
Brexanolone Lifting Outcomes Of Moms
- Age
- 15 – 45
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Lipocine Inc. · Industry
This trial is looking for women aged 15 to 45 who are experiencing severe postpartum depression. Participants will take the study drug LPCN 1154A to see if it helps reduce their depressive symptoms and to learn about any side effects.
You may be able to join if
- I am a female between 15 and 45 years old.
- I have had a depressive episode that started during my pregnancy or within 4 weeks after giving birth.
- I am less than 18 months postpartum at the time of screening.
- I have a severe level of depression as measured by a specific scale.
You may not be able to join if
- I have a history of bipolar disorder.
- I have a history of schizophrenia or schizoaffective disorder.
- I am currently experiencing active psychosis.
- I have had suicidal behavior related to my current depressive episode.
- I have had a seizure within the last 6 months.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause
Loading trial locations…